Bellus Health

Investors & Media

Press Releases

Press Releases

9/23/21
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
Topline results from both studies are expected in December 2021 LAVAL, Quebec --(BUSINESS WIRE)--Sep. 23, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory
Displaying 1 - 10 of 17